GT Biopharma (GTBP) Stock: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$5.34
-0.07 (-1.21%)
▼
5d:
-27.38%
30d:
-24.72%
90d:
+1548.1%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GTBP is down 27.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GTBP is down 27.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $5.34, which is considered oversold relative to its 30-day fair value range of $5.78 to $8.06.
Technical Outlook: Technically, GTBP is in a strong uptrend. The price is currently testing key support at $5.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $75.00 (+1286.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GTBP is in a strong uptrend. The price is currently testing key support at $5.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $75.00 (+1286.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.78 -
$8.06
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1286.3% below Wall St target ($75.00)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.78 -
$8.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.31
Resistance Level
$7.50
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.68
Wall Street Target
$75.00
(+1286.3%)
Share & Embed Analysis
Last updated: October 22, 2026 10:22 AM ET
Data refreshes hourly during market hours. Next update: 11:22 AM
Data refreshes hourly during market hours. Next update: 11:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 71 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
